Halozyme Therapeutics (NASDAQ:HALO) is scheduled to issue its quarterly earnings data after the market closes on Thursday, February 21st. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Halozyme Therapeutics stock opened at $16.60 on Thursday. Halozyme Therapeutics has a one year low of $13.24 and a one year high of $21.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.09 and a quick ratio of 2.96. The stock has a market cap of $2.41 billion, a PE ratio of 36.89 and a beta of 1.75.
HALO has been the subject of a number of recent research reports. Cantor Fitzgerald set a $27.00 price objective on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 6th. ValuEngine upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. Finally, Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research note on Tuesday, November 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $20.43.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Modern Readers and is owned by of Modern Readers. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.modernreaders.com/news/2019/02/14/halozyme-therapeutics-halo-scheduled-to-post-quarterly-earnings-on-thursday.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More: What is cost of equity?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.